{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31232459", "DateCompleted": {"Year": "2020", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2022", "Month": "09", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "06", "Day": "24"}], "Language": ["eng"], "ELocationID": ["CD013106", "10.1002/14651858.CD013106.pub2"], "Journal": {"ISSN": "1469-493X", "JournalIssue": {"Volume": "6", "Issue": "6", "PubDate": {"Year": "2019", "Month": "Jun", "Day": "24"}}, "Title": "The Cochrane database of systematic reviews", "ISOAbbreviation": "Cochrane Database Syst Rev"}, "ArticleTitle": "Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B.", "Pagination": {"StartPage": "CD013106", "MedlinePgn": "CD013106"}, "Abstract": {"AbstractText": ["Hepatitis B virus (HBV) infection is a liver disease caused by hepatitis B virus, which may lead to serious complications such as cirrhosis and hepatocellular carcinoma. People with HBV infection may also have coinfections including HIV and other hepatitis viruses (hepatitis C or D), and coinfections may increase the risk of all-cause mortality. Chronic HBV infection increases morbidity, psychological stress, and it is an economic burden on people with chronic hepatitis B and their families. Radix Sophorae flavescentis, a herbal medicine, is administered mostly in combination with other drugs or herbs. It is believed that it decreases discomfort and prevents the replication of the virus in people with chronic hepatitis B. However, the benefits and harms of Radix Sophorae flavescentis on patient-centred outcomes are unknown, and its wide usage has never been established with rigorous review methodology.", "To assess the benefits and harms of Radix Sophorae flavescentis versus other drugs or herbs in people with chronic hepatitis B.", "We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, and seven other databases to December 2018. We also searched the World Health Organization International Clinical Trials Registry Platform (www.who.int/ictrp), ClinicalTrials.gov (www.clinicaltrials.gov/), and the Chinese Clinical Trial Registry for ongoing or unpublished trials to December 2018.", "We included randomised clinical trials, irrespective of publication status, language, or blinding, comparing Radix Sophorae flavescentis versus other drugs or herbs for people with chronic hepatitis B. In addition to chronic hepatitis B, participants could also have had cirrhosis, hepatocellular carcinoma, or any other concomitant disease. We excluded polyherbal blends containing Radix Sophorae flavescentis. We allowed cointerventions when the cointerventions were administered equally to all intervention groups.", "Review authors in pairs individually retrieved data from published reports and after correspondence with investigators. Our primary outcomes were all-cause mortality, serious adverse events, and health-related quality of life. Our secondary outcomes were hepatitis B-related mortality, hepatitis B-related morbidity, and adverse events considered 'not to be serious'. We presented the meta-analysed results as risk ratios (RR) with 95% confidence intervals (CI). We assessed the risk of bias using domains with predefined definitions. We conducted Trial Sequential Analyses to control the risks of random errors. We used GRADE methodology to evaluate our certainty in the evidence (i.e. \"the extent of our confidence that the estimates of the effect are correct or are adequate to support a particular decision or recommendation\").", "We included 10 randomised clinical trials with 898 participants. We judged all trials at high risk of bias. The trials covered oral capsules, intravenous infusion, intramuscular injection, and acupoint (a specifically chosen site of acupuncture) injection of Radix Sophorae flavescentis with a follow-up period from 1 to 12 months. The drugs being used as a comparator were lamivudine, adefovir, interferon, tiopronin, thymosin, or other Chinese herbs. Two trials included children up to 14 years old. Participants in one trial had cirrhosis in chronic hepatitis B. None of the trials reported all-cause mortality, health-related quality of life, serious adverse events, hepatitis B-related mortality, or morbidity. We are uncertain as to whether Radix Sophorae flavescentis has a beneficial or harmful effect on adverse events considered 'not to be serious' (RR 0.86, 95% CI 0.42 to 1.75; I<sup>2</sup> = 0%; 2 trials, 163 participants; very low-certainty evidence), as well as if it decreases or increases the proportion of participants with detectable HBV-DNA (RR 1.14, 95% CI 0.81 to 1.63; I<sup>2</sup> = 92%; 8 trials, 719 participants; very low-certainty evidence). Radix Sophorae flavescentis showed a reduction in the proportion of participants with detectable hepatitis B virus e-antigen (HBeAg) (RR 0.86, 95% CI 0.75 to 0.98; I<sup>2</sup> = 43%; 7 trials, 588 participants; very low-certainty evidence).Two of the 10 trials were not funded, and one received academic funding. The remaining seven trials provided no information on funding.The randomisation process in another 109 trials was insufficiently reported to ensure the inclusion of any of these studies in our review.", "The included trials lacked data on all-cause mortality, health-related quality of life, serious adverse events, hepatitis-B related mortality, and hepatitis-B related morbidity. The evidence on the effect of Radix Sophorae flavescentis on the proportion of participants with adverse events considered 'not to be serious' and on the proportion of participants with detectable HBV-DNA is still unclear. We advise caution regarding the results of Radix Sophorae flavescentis showing a reduction in the proportion of people with detectable HBeAg because the trials were at high risk of bias, because it is a non-validated surrogate outcome, and because of the very low certainty in the evidence. As we were unable to obtain information on a large number of studies regarding their trial design, we were deterred from including them in our review. Undisclosed funding may have influence on trial results and lead to poor design of the trial. In view of the wide usage of Radix Sophorae flavescentis, we need large, unbiased, high-quality placebo-controlled randomised trials assessing patient-centred outcomes."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Bei San Huan Dong Lu 11, Chaoyang District, Beijing, China, 100029."}], "LastName": "Liang", "ForeName": "Ning", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Kong", "ForeName": "De Zhao", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Lu", "ForeName": "Chun Li", "Initials": "CL"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Ma", "ForeName": "Si Si", "Initials": "SS"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Li", "ForeName": "Yu Qi", "Initials": "YQ"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Nikolova", "ForeName": "Dimitrinka", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Jakobsen", "ForeName": "Janus C", "Initials": "JC"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Gluud", "ForeName": "Christian", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Liu", "ForeName": "Jian Ping", "Initials": "JP"}], "GrantList": [{"GrantID": "R24 AT001293", "Acronym": "AT", "Agency": "NCCIH NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article", "Meta-Analysis", "Research Support, N.I.H., Extramural", "Research Support, Non-U.S. Gov't", "Systematic Review"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Cochrane Database Syst Rev", "NlmUniqueID": "100909747", "ISSNLinking": "1361-6137"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "DNA, Viral"}, {"RegistryNumber": "0", "NameOfSubstance": "Hepatitis B e Antigens"}], "CommentsCorrectionsList": [{"RefSource": "doi: 10.1002/14651858.CD013106"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Adolescent"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["adverse effects", "therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Child"}, {"QualifierName": ["analysis"], "DescriptorName": "DNA, Viral"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["blood"], "DescriptorName": "Hepatitis B e Antigens"}, {"QualifierName": ["genetics"], "DescriptorName": "Hepatitis B virus"}, {"QualifierName": ["drug therapy", "virology"], "DescriptorName": "Hepatitis B, Chronic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["adverse effects", "chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["statistics & numerical data"], "DescriptorName": "Randomized Controlled Trials as Topic"}, {"QualifierName": ["adverse effects", "chemistry"], "DescriptorName": "Sophora"}], "CoiStatement": "NL: none known.\u2028\nDZK: none known.\u2028\nCLL: none known.\u2028\nSSM: none known.\u2028\nYQL: none known.\u2028\nDN: none known.\u2028\nJCJ: none known.\u2028\nCG: none known.\u2028\nJPL: none known."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Deng HP. Clinical observation on the therapeutic efficacy of matrine on chronic hepatitis B with hyperbilirubinemia. International Journal of Traditional Chinese Medicine 2010;32(3):229, 231."}], "Title": "Deng 2010 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Huang YQ, Lin ZH, Ji SM, Xu ZJ, Wang CG. Clinical study of the interferon a\u20102b combined with kurorinone in the treatment of chronic hepatitis B. Chinese Journal of Infectious Diseases 2004;22(4):259\u201062."}], "Title": "Huang 2004 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Huang YQ, Lin ZH, Ji SM, Xu ZJ. Clinical study of treatment of chronic hepatitis B with kurorinone combined with thymosin. Medical Journal of Chinese People's Liberation Army 2005;30(12):1100\u20102."}], "Title": "Huang 2005 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Liang J, Xu CY, Qi SH. Ku shen su capsules for treating chronic hepatitis B. Chinese Journal of Trauma and Disability Medicine 2006;14(3):40."}], "Title": "Liang 2006 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang J. Clinical observation of adefovir dipivoxil in the treatment of hepatitis B patients with HBeAg positive. Chinese Journal of Primary Medicine Pharmacy 2013;20(7):986\u20108."}], "Title": "Wang 2013 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Xi RH, Li HC, Luo YP, Xi YN. Matrine injections combined with liver protective drugs for children with chronic hepatitis B [\u82e6\u53c2\u78b1\u6ce8\u5c04\u6db2\u8054\u5408\u62a4\u809d\u7247\u6cbb\u7597\u513f\u7ae5\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u7814\u7a76]. Journal of Gansu College of Traditional Chinese Medicine 2010;27(4):36\u20109."}], "Title": "Xi 2010 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Xu JP, Huang C, Bao B, Li G, Nu ET. Clinic study of treating chronic hepatitis B and cirrhosis with matrine and glucose injection. China Synthesis Medicine 2003;4(2):103\u20104."}], "Title": "Xu 2003 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Yan ZP, Xu TT, Su KL, Wang C, Yan T, Hua Z, et al. Investigation of therapeutic effect of Longchai formula granule on chronic hepatitis B patients: a double\u2010blind, controlled and randomized clinical trial. BIO Web of Conferences 2017;8(2017):1029. [DOI: ]"}], "Title": "Yan 2017 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhang XW. Clinical Significance of Serum HBsAg Quantitative Detection in Patients with Chronic Hepatitis B and the Controlled Study on the Treatment Effects on HBsAg between Lamivudine and Oxymatrine [Masters dissertation]. Hefei (China): Anhui Medical University, 2007."}], "Title": "Zhang 2007 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhang HM, Niu ZM, Hu J, Liu HF. Effect of lamivudine combined with matrine on treating children with chronic hepatitis B. Research of Integrated Traditional Chinese and Western Medicine 2011;3(3):121\u20103, 126."}], "Title": "Zhang 2011 {published data only}"}], "Reference": [], "Title": "References to studies included in this review"}, {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Cao XG, Cai LJ. The inhibition of kurarinone on hepatitis B. Chinese Journal of Biochemical Pharmaceutics 2007;28(1):58\u20109."}], "Title": "Cao 2007 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Chen CX, Guo SM, Liu B. A randomized controlled trial of kurorinone versus interferon\u2010alpha2a treatment in patients with chronic hepatitis B. Journal of Viral Hepatitis 2000;7(3):225\u20109.", "ArticleIdList": ["10849265"]}], "Title": "Chen 2000 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Chen YX, Shi JH, Yang YQ. Clinical observation on treatment of chronic hepatitis B with ku shen su injection [\u82e6\u53c2\u7d20\u6ce8\u5c04\u6db2\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u89c2\u5bdf]. Occupation and Health 2001;17(9):117\u20108."}], "Title": "Chen 2001 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Chen XL, Hua LJ, Peng HB. Clinical observation of oxymatrine in the treatment of chronic hepatitis B in children [\u82e6\u53c2\u7d20\u6cbb\u7597\u5c0f\u513f\u6162\u6027\u4e59\u578b\u809d\u708e\u7684\u4e34\u5e8a\u89c2\u5bdf]. Chinese Journal of Clinical Medicine Research 2004;10(112):11744\u20105."}], "Title": "Chen 2004 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Chen LY. Clinical observation of adefovir dipivoxil in the treatment of chronic hepatitis B [\u963f\u5fb7\u798f\u97e6\u916f\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u89c2\u5bdf]. The First National Conference on Difficult and Serious Liver Diseases, the Fourth National Annual Conference on Artificial Liver and Blood Purification; 2008 Sep 3\u20105; Nanchang (Jiangxi, China). 2008."}], "Title": "Chen 2008 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Cui GY. Comparison of the efficacy of Bortali injection and a\u2010interferon in the treatment of chronic hepatitis B [\u535a\u5c14\u6cf0\u529b\u6ce8\u5c04\u6db2\u4e0e\u03b1\u2010\u5e72\u6270\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u7597\u6548\u6bd4\u8f83]. Chinese Journal of Rural Medicine and Pharmacy 2006;13(1):21."}], "Title": "Cui 2006 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Gong XQ, Lin ZX, Chen S. Clinical study of oxymatrine combined with interferon in the treatment of chronic hepatitis B [\u82e6\u53c2\u7d20\u8054\u5408\u5e72\u6270\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u7814\u7a76]. Nei Mongol Journal of Traditional Chinese Medicine 2010;26(12):80\u20101."}], "Title": "Gong 2010 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Hu B, Wang YL, Zhu L, Li JK, Li F, Jiang S. Therapeutic effect of thymosin \u03b11 combined with oxymatrine capsule on lamivudine\u2010resistant chronic hepatitis B [\u80f8\u817a\u80bd\u03b11\u8054\u5408\u82e6\u53c2\u7d20\u80f6\u56ca\u6cbb\u7597\u62c9\u7c73\u592b\u5b9a\u8010\u836f\u7684\u6162\u6027\u4e59\u578b\u809d\u708e\u7597\u6548\u89c2\u5bdf]. Journal of Clinical Hepatology 2006;22(6):429\u201031."}], "Title": "Hu 2006 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Jiang M, Ling YW, Hu HM. Clinical observation of lamivudine combined with oxymatrine in the treatment of chronic hepatitis B. Seek Medical and Ask the Medicine 2013;11(5):312."}], "Title": "Jiang 2013 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Jiao JZ, Ge QL, Chen GP, Zhu P, Wang XL, Ma JL. Clinical study on matrine for the treatment of chronic hepatitis B. Medical Journal of National Defending Forces in Northwest China 2003;24(4):272\u20103."}], "Title": "Jiao 2003 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Jin XH, Wang YG. Cost effectiveness analysis of three methods in the treatment of chronic viral hepatitis B. Strait Pharmaceutical Journal 2008;20(8):139\u201040."}], "Title": "Jin 2008 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Li BF. Long\u2010term efficacy of oxymatrine in the treatment of chronic hepatitis B [\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u809d\u8fdc\u671f\u7597\u6548\u89c2\u5bdf]. Central Plains Medical Journal 2004;31(17):53."}], "Title": "Li 2004 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Li WJ, Mao BR, Li XL, Xin J. Clinical observation on treatment of chronic hepatitis B with Tianqing Fuxin [\u5929\u6674\u590d\u6b23\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u7597\u6548\u89c2\u5bdf]. Journal of Modern Clinical Medicine 2006;32(5):337\u20108."}], "Title": "Li 2006a {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Li GH. Comparison of the curative effect of the oxymatrine and \u03b1\u2010interferon. Journal of Handan Medical College 2006;19(2):105\u20106."}], "Title": "Li 2006b {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Li L, Liao QH. Clinical observation on 196 cases of chronic hepatitis B treated with oxymatrine [\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e196\u4f8b\u4e34\u5e8a\u89c2\u5bdf]. The 9th Zhejiang Provincial Conference on Integrated Traditional and Western Medicine for Liver Diseases; 2006 Jun 1; Pujiang (Zhejiang, China). 2006:117\u201020."}], "Title": "Li 2006c {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Li BM, Zhang QW, Yao SX. Comparison of the efficacy of thymosin \u03b11 and oxymatrine capsules in the treatment of hepatitis B virus carriers during immune tolerance [\u80f8\u817a\u80bd\u03b11\u4e0e\u82e6\u53c2\u7d20\u80f6\u56ca\u6cbb\u7597\u514d\u75ab\u8010\u53d7\u671f\u4e59\u809d\u75c5\u6bd2\u643a\u5e26\u8005\u7597\u6548\u5bf9\u6bd4\u89c2\u5bdf]. Medical Information 2013;26(2):152\u20103."}], "Title": "Li 2013 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Liu AP, Pang XY, Gu YN, Wang KL, Sun CP. Clinical observation of matrine for anti\u2010fibrosis. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2001;11(2):71\u20102."}], "Title": "Liu 2001a {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Liu TD, Zhu L, Ding XQ. Treatment of 28 cases of chronic hepatitis B with oxymatrine combined with acyclovir [\u82e6\u53c2\u7d20\u8054\u5408\u963f\u6614\u6d1b\u97e6\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e28\u4f8b]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2001;11(1):38\u20109."}], "Title": "Liu 2001b {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Liu ZS, Xu JH, Zhao GL, Li GC. Observation on 40 cases of chronic hepatitis B treated with oxymatrine [\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e40\u4f8b\u89c2\u5bdf]. 2002 National Conference on Integrative Medicine for Liver Diseases; 2002 Aug 9\u201011; Guiyang (Guizhou, China). 2002:73\u20104."}], "Title": "Liu 2002 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Pan ZS, She QH, Yan H, Zhang YB. Clinical study on treatment of chronic hepatitis B by kurarinone combined with interferon \u03b1\u20101b. Chinese Journal of Integrated Traditional and Western Medicine 2005;28(8):700\u20103.", "ArticleIdList": ["16152825"]}], "Title": "Pan 2005 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Qin SJ. Curative effect observation of 90 cases of chronic hepatitis B treated with oxymatrine [\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e90\u4f8b\u7597\u6548\u89c2\u5bdf]. Journal of Zhengzhou University (Medical Sciences) 2003;38(5):829."}], "Title": "Qin 2003 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "She HY, Wu XH, Zhang JM, Feng ZZ. Effects of oxymatrine on the patients with chronic hepatitis B. Ningbo Yi Xue 2000;12(9):409\u201010."}], "Title": "She 2000 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Song LC, Zhang GH, Huai DG, Zhang LY, Zhao J. Forty\u2010six cases of chronic hepatitis B treated with acupoint injection of matrine [\u82e6\u53c2\u7d20\u6ce8\u5c04\u6db2\u7a74\u4f4d\u6ce8\u5c04\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e46\u4f8b]. China Foreign Medical Treatment 2008;3(23):66\u20107."}], "Title": "Song 2008 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Su GY. Comparison of clinical efficacy between bicyclol and oxymatrine in the treatment of chronic hepatitis B [\u53cc\u73af\u9187\u4e0e\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u7597\u6548\u5bf9\u6bd4]. Compilation of the 2006 Conference on Infectious Diseases and Liver Diseases in Zhejiang Province; 2006 Oct 1; Ningbo (Zhejiang, China). 2006:238\u20109."}], "Title": "Su 2006 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Sui YH, Xu J, Guo YY, Zhang X, Li X. Kurorinone combined with thymus peptide in the treatment of chronic hepatitis B. Clinical Medicine 2006;26(10):17\u20108."}], "Title": "Sui 2006 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Sun YX, Zhang J, Yi MB. Clinical observation of oxymatrine in the treatment of chronic hepatitis B [\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u89c2\u5bdf]. Chinese Journal of Urban and Rural Industrial Hygiene 2002;16(6):40."}], "Title": "Sun 2002 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Sun BJ. Clinical study of adefovir dipivoxil in the treatment of HBeAg\u2010positive and HBeAg\u2010negative chronic hepatitis B [\u963f\u5fb7\u798f\u97e6\u916f\u6cbb\u7597HBeAg\u9633\u6027\u548cHBeAg\u9634\u6027\u7684\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u7814\u7a76]. The 10th National Conference on Liver Diseases and the 10th Anniversary of the Chinese Journal of Liver Diseases; 2006 May 11\u201015; Dalian (Liaoning, China). 2006:276."}], "Title": "Sun 2006 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Tang SH, Peng HB. Clinical observation on treatment of 52 cases of chronic hepatitis B in children with oxymatrine [\u82e6\u53c2\u7d20\u6cbb\u7597\u5c0f\u513f\u6162\u6027\u4e59\u578b\u809d\u708e52\u4f8b\u4e34\u5e8a\u89c2\u5bdf]. Chinese Journal of Current Clinical Medicine 2005;3(10):945\u20107."}], "Title": "Tang 2005 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang QH, Zhu LM, Zhang QB, Xu DZ, Guo YB, Wang ZQ, et al. Research of medical treatment novel program on the chronic viral hepatitis B. Bulletin of Medical Research 2001;30(4):8\u201011."}], "Title": "Wang 2001 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang JP, Yue XY, Sun XY. Therapeutic effect of oxymatrine injection on chronic hepatitis B [\u82e6\u53c2\u7d20\u6ce8\u5c04\u6db2\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u7597\u6548\u89c2\u5bdf]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 2003;3(2):10."}], "Title": "Wang 2003 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang C, Wang XW. Comparison of short\u2010term effects of lamivudine combined with liver protective tablets or matrine in the treatment of chronic hepatitis B [\u62c9\u7c73\u592b\u5b9a\u8054\u5408\u62a4\u809d\u7247\u6216\u82e6\u53c2\u78b1\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u8fd1\u671f\u7597\u6548\u6bd4\u8f83]. Journal of Guiyang College of Traditional Chinese Medicine 2006;28(1):20\u20102."}], "Title": "Wang 2006a {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang ZM, Lin WL. Observing the efficacy of oxymartine and Interferon together treating 36 patients with chronic hepatitis B. Drug Evaluation 2006;3(5):366\u20107."}], "Title": "Wang 2006b {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang MH, Liu F, Chen DS, Liu XZ, Yao GF. Therapeutic effect of adefovir dipivoxil on 72 patients with chronic hepatitis B [\u963f\u5fb7\u798f\u97e6\u916f\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e72\u4f8b\u7597\u6548\u89c2\u5bdf]. Infectious Disease Information 2007;20(4):239\u201040."}], "Title": "Wang 2007 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang YJ, Rong X, Zhu JL. Clinical efficacy of matrine injection in the treatment of chronic hepatitis B [\u82e6\u53c2\u78b1\u6ce8\u5c04\u6db2\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u4e34\u5e8a\u7597\u6548\u5206\u6790]. Laboratory Medicine and Clinic 2009;6(3):219."}], "Title": "Wang 2009 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Wu GQ, Liu LC, Cai LQ, Wen B, Jiang Y, Zhong XH, et al. Clinical observation of high dose hepatitis B vaccine combined with vaccae in the treatment of chronic HBV carriers [\u9ad8\u5242\u91cf\u4e59\u809d\u75ab\u82d7\u8054\u5408\u5fae\u5361\u6cbb\u7597\u6162\u6027HBV\u643a\u5e26\u8005\u7684\u4e34\u5e8a\u89c2\u5bdf]. China Healthcare Innovation 2009;4(16):20\u20101."}], "Title": "Wu 2009 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Xia T, Sun H. Remote effect of oxymatrine on chronic hepatitis B. Modern Journal of Integrated Traditional Chinese and Western Medicine 2003;12(24):2631\u20102."}], "Title": "Xia 2003 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Xiao GB. The ester and oxymatrine treatment of chronic hepatitis B. Medical Aesthetics and Cosmetology 2013;16(3):44."}], "Title": "Xiao 2013 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Xie BH. Clinical study of oxymatrine combined with adenosine monophosphate in the treatment of chronic hepatitis B [\u82e6\u53c2\u7d20\u8054\u7528\u5355\u78f7\u9178\u963f\u7cd6\u817a\u82f7\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u7684\u4e34\u5e8a\u7814\u7a76]. Tianjin Journal of Traditional Chinese Medicine 2003;20(4):36\u20107."}], "Title": "Xie 2003 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Xue C. Clinical efficacy of aspartate ornithine in the treatment of hepatitis B cirrhosis [\u95e8\u51ac\u6c28\u9178\u9e1f\u6c28\u9178\u6cbb\u7597\u4e59\u578b\u809d\u708e\u809d\u786c\u5316\u7684\u4e34\u5e8a\u7597\u6548\u4f53\u4f1a]. China Health Care Nutrition 2016;26(5):107\u20108."}], "Title": "Xue 2016 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Yang QY. Clinical observation of oxymatrine against liver fibrosis [\u82e6\u53c2\u7d20\u6297\u809d\u7ea4\u7ef4\u5316\u7684\u4e34\u5e8a\u89c2\u5bdf]. Anti\u2010Infection Pharmacy 2005;2(1):22."}], "Title": "Yang 2005 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Yu YY, Si CW, Zeng Z, Wang QH, Zhou XQ, Zhang QB, et al. A clinical research on oxymatrine for the treatment of chronic hepatitis B. Chinese Journal of Hepatology 2002;10(4):280\u20102.", "ArticleIdList": ["12223140"]}], "Title": "Yu 2002 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhang MX, Li J, Jiang BL. Treatment of 89 cases of chronic hepatitis B with Bortalin injection [\u535a\u5c14\u6cf0\u529b\u6ce8\u5c04\u6db2\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e89\u4f8b]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2001;11(4):226\u20107."}], "Title": "Zhang 2001b {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhong JD. Therapeutic effect of interferon combined with oxymatrine on chronic hepatitis B [\u5e72\u6270\u7d20\u8054\u5408\u82e6\u53c2\u7d20\u6cbb\u7597\u6162\u6027\u4e59\u578b\u809d\u708e\u7597\u6548\u89c2\u5bdf]. China Foreign Medical Treatment 2008;11(2):8."}], "Title": "Zhong 2008 {published data only}"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhou HX. The clinical effects of glutathione auxiliary in the treatment of chronic hepatitis B liver fibrosis. China Medicine and Pharmacy 2014;4(7):96\u20107, 120."}], "Title": "Zhou 2014 {published data only}"}], "Reference": [], "Title": "References to studies excluded from this review"}, {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore, Md.) 2016;63(1):261\u201083.", "ArticleIdList": ["PMC5987259", "26566064"]}], "Title": "AASLD 2016"}, {"ReferenceList": [], "Reference": [{"Citation": "Al\u2010Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet 2014;383(9912):176\u201085.", "ArticleIdList": ["PMC3952153", "24411646"]}], "Title": "Al\u2010Shahi Salman 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Alizadeh AH, Ranjbar M, Yadollahzadeh M. Patient concerns regarding chronic hepatitis B and C infection. Eastern Mediterranean Health Journal 2008;14(5):1142\u20107.", "ArticleIdList": ["19161087"]}], "Title": "Alizadeh 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401\u20106.", "ArticleIdList": ["21208779"]}], "Title": "Balshem 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta\u2010analyses. Journal of Clinical Epidemiology 2008;61(8):763\u20109.", "ArticleIdList": ["18411040"]}], "Title": "Brok 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta\u2010analyses may be inconclusive \u2013 trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta\u2010analyses. International Journal of Epidemiology 2009;38(1):287\u201098.", "ArticleIdList": ["18824466"]}], "Title": "Brok 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to formulate research recommendations. BMJ (Clinical Research Ed.) 2006;333(7572):804\u20106.", "ArticleIdList": ["PMC1602035", "17038740"]}], "Title": "Brown 2006"}, {"ReferenceList": [], "Reference": [{"Citation": "Castellini G, Nielsen EE, Gluud C. Comment on: \"Cell therapy for heart disease: trial sequential analyses of two Cochrane Reviews\". Clinical Pharmacology and Therapeutics 2017;102:21\u20104.", "ArticleIdList": ["27727441"]}], "Title": "Castellini 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Castellini G, Bruschettini M, Gianola S, Gluud C, Moja L. Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews 2018;7(110):1\u201010. [DOI: 10.1186/s13643-018-0770-1]", "ArticleIdList": ["10.1186/s13643-018-0770-1", "PMC6064621", "30055658"]}], "Title": "Castellini 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;374(9683):86\u20109.", "ArticleIdList": ["19525005"]}], "Title": "Chalmers 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet 2014;383(9912):156\u201065.", "ArticleIdList": ["24411644"]}], "Title": "Chalmers 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Chan K, Zhang HW, Lin ZX. Treatments used in complementary and alternative medicine. Side Effects of Drugs Annual 2011;33:989\u20101007."}], "Title": "Chan 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle A\u2010Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200\u20107.", "ArticleIdList": ["PMC5114123", "23295957"]}], "Title": "Chan 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "Nanjing University of Traditional Chinese Medicine. Dictionary of Traditional Chinese Medicine. 2nd Edition. Shanghai (China): Shanghai Science and Technology Publishing House, 2006."}], "Title": "Chinese Herbal Dictionary 2006"}, {"ReferenceList": [], "Reference": [{"Citation": "The Tenth Pharmacopoeia Commission. The Pharmacopoeia of People's Republic of China. 10th Edition. Beijing (China): China Medical Science Press, 2015."}], "Title": "Chinese Pharmacopoeia 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "Ciani O, \u00a0Buyse M, \u00a0Drummond M, \u00a0Rasi G, \u00a0Saad ED, \u00a0Taylor RS. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health 2017;20(3):487\u201095.", "ArticleIdList": ["28292495"]}], "Title": "Ciani 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology, Chinese Medical Association. Viral hepatitis prevention and treatment guideline. Chinese Journal of Internal Medicine 2001;40(1):62\u20108."}], "Title": "CMA 2001"}, {"ReferenceList": [], "Reference": [{"Citation": "Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2005 version). Chinese Journal of Hepatology 2005;13(12):881\u201091.", "ArticleIdList": ["16491521"]}], "Title": "CMA 2005"}, {"ReferenceList": [], "Reference": [{"Citation": "Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chinese Journal of Preventive Medicine 2011;12(1):1\u201015.", "ArticleIdList": ["21272453"]}], "Title": "CMA 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Derikx MH, Spanier BW, Vrolijk JM. Hepatitis B; sometimes co\u2010infection with hepatitis D [Hepatitis B; soms ook samen met hepatitis D]. Nederlands Tijdschrift voor Geneeskunde 2011;155:A3513.", "ArticleIdList": ["21854665"]}], "Title": "Derikx 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Dong Y, Xi H, Yu Y, Wang Q, Jiang K, Li L. Effects of oxymatrine on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti\u2010hepatitis B virus mechanism of oxymatrine. Journal of Gastroenterology and Hepatology 2002;17(12):1299\u2010306.", "ArticleIdList": ["12423275"]}], "Title": "Dong 2002"}, {"ReferenceList": [], "Reference": [{"Citation": "European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012;57(1):167\u201085.", "ArticleIdList": ["22436845"]}], "Title": "EASL 2012"}, {"ReferenceList": [], "Reference": [{"Citation": "European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Journal of Hepatology 2017;67(2):370\u201098.", "ArticleIdList": ["28427875"]}], "Title": "EASL 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta\u2010analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629\u201034.", "ArticleIdList": ["PMC2127453", "9310563"]}], "Title": "Egger 1997"}, {"ReferenceList": [], "Reference": [{"Citation": "Ezbarami ZT, Hassani P, Tafreshi MZ, Majd HA. A qualitative study on individual experiences of chronic hepatitis B patients. Nursing Open 2017;4(4):310\u20108.", "ArticleIdList": ["PMC5653392", "29085657"]}], "Title": "Ezbarami 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Fisher RA. On the interpretation of X2 from contingency tables, and the calculation of P. Journal of the Royal Statistical Society 1922;85(1):87\u201094."}], "Title": "Fisher 1922"}, {"ReferenceList": [], "Reference": [{"Citation": "Fleming TR, \u00a0Powers JH. Biomarkers and surrogate endpoints in clinical trials. Statistics in Medicine 2012;31(25):2973\u201084.", "ArticleIdList": ["PMC3551627", "22711298"]}], "Title": "Fleming 2012"}, {"ReferenceList": [], "Reference": [{"Citation": "Gartlehner G, Nussbaumer\u2010Streit B, Wagner G, Patel S, Swinson\u2010Evans T, Dobrescu A, et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology 2019; Vol. 106:50\u20109. [DOI: 10.1016/j.jclinepi.2018.10.009]", "ArticleIdList": ["10.1016/j.jclinepi.2018.10.009", "30342970"]}], "Title": "Gartlehner 2019"}, {"ReferenceList": [], "Reference": [{"Citation": "Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet 2014;383(9913):267\u201076.", "ArticleIdList": ["24411647"]}], "Title": "Glasziou 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46(4):734\u201042.", "ArticleIdList": ["17316871"]}], "Title": "Gluud 2007"}, {"ReferenceList": [], "Reference": [{"Citation": "Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005;34(6):1329\u201039.", "ArticleIdList": ["16249217"]}], "Title": "Goldstein 2005"}, {"ReferenceList": [], "Reference": [{"Citation": "Gong ZF. A case report of respiratory muscle paralysis caused by matrine. Lishizhen Medicine and Materia Medica Research 2000;2(5):466."}], "Title": "Gong 2000"}, {"ReferenceList": [], "Reference": [{"Citation": "GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations, 2013. guidelinedevelopment.org/handbook (accessed prior to 30 May 2019)."}], "Title": "GRADE 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 16 November 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015."}], "Title": "GRADEpro GDT [Computer program]"}, {"ReferenceList": [], "Reference": [{"Citation": "Gu JY. Allergic drug eruption caused by Kushensu. Chinese Journal of Pharmacoepidemiology 2008;17(1):61."}], "Title": "Gu 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso\u2010Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence \u2013 imprecision. Journal of Clinical Epidemiology 2011;64(12):1283\u201093. [PUBMED: 21839614]", "ArticleIdList": ["21839614"]}], "Title": "Guyatt 2011a"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence \u2013 publication bias. Journal of Clinical Epidemiology 2011;64(12):1277\u201082. [PUBMED: 21802904]", "ArticleIdList": ["21802904"]}], "Title": "Guyatt 2011b"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso\u2010Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311\u20106. [PUBMED: 21802902]", "ArticleIdList": ["21802902"]}], "Title": "Guyatt 2011c"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence \u2013 inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294\u2010302. [PUBMED: 21803546]", "ArticleIdList": ["21803546"]}], "Title": "Guyatt 2011d"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence \u2013 indirectness. Journal of Clinical Epidemiology 2011;64(12):1303\u201010. [PUBMED: 21802903]", "ArticleIdList": ["21802903"]}], "Title": "Guyatt 2011e"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395\u2010400. [PUBMED: 21194891]", "ArticleIdList": ["21194891"]}], "Title": "Guyatt 2011f"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso\u2010Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence \u2013 study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407\u201015. [PUBMED: 21247734]", "ArticleIdList": ["21247734"]}], "Title": "Guyatt 2011g"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383\u201094. [PUBMED: 21195583]", "ArticleIdList": ["21195583"]}], "Title": "Guyatt 2011h"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso\u2010Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013;66(2):151\u20107. [PUBMED: 22542023]", "ArticleIdList": ["22542023"]}], "Title": "Guyatt 2013a"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables \u2013 binary outcomes. Journal of Clinical Epidemiology 2013;66(2):158\u201072. [PUBMED: 22609141]", "ArticleIdList": ["22609141"]}], "Title": "Guyatt 2013b"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles \u2013 continuous outcomes. Journal of Clinical Epidemiology 2013;66(2):173\u201083. [PUBMED: 23116689]", "ArticleIdList": ["23116689"]}], "Title": "Guyatt 2013c"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt G, Andrews J, Oxman AD, Alderson P, Dahm P, Falck\u2010Ytter Y, et al. GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology 2013;66(7):719\u201025.", "ArticleIdList": ["23312392"]}], "Title": "Guyatt 2013d"}, {"ReferenceList": [], "Reference": [{"Citation": "Guyatt GH, Ebrahim S, Alonso\u2010Coello P, Johnston BC, Mathioudakis AG, Briel M, et al. GRADE guidelines: 17. Assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology 2017;87:14\u201022. [PUBMED: 28529188]", "ArticleIdList": ["28529188"]}], "Title": "Guyatt 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Harbord RM, Egger M, Sterne JAC. A modified test for small\u2010study effects in meta\u2010analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443\u201057.", "ArticleIdList": ["16345038"]}], "Title": "Harbord 2006"}, {"ReferenceList": [], "Reference": [{"Citation": "He M. Lamivudine matrine combination therapy for chronic hepatitis B: a systematic review. Lishizhen Medicine and Materia Medica Research 2013;24(4):944\u20106."}], "Title": "He 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "Higgins JP, Thompson SG. Quantifying heterogeneity in a meta\u2010analysis. Statistics in Medicine 2002;21(11):1539\u201058.", "ArticleIdList": ["12111919"]}], "Title": "Higgins 2002"}, {"ReferenceList": [], "Reference": [{"Citation": "Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta\u2010analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557\u201060.", "ArticleIdList": ["PMC192859", "12958120"]}], "Title": "Higgins 2003"}, {"ReferenceList": [], "Reference": [{"Citation": "Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org."}], "Title": "Higgins 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Hou JL, Liu ZH, Gu F. Epidemiology and prevention of hepatitis B virus infection. International Journal of Medical Sciences 2005;2(1):50\u20107.", "ArticleIdList": ["PMC1142225", "15968340"]}], "Title": "Hou 2005"}, {"ReferenceList": [], "Reference": [{"Citation": "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting E2A. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf (accessed 2 November 2018)."}], "Title": "ICH\u2010E2A 1994"}, {"ReferenceList": [], "Reference": [{"Citation": "International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline. Integrated Addendum to ICH E6(R1): guideline for good clinical practice E6(R2). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4_2016_1109.pdf (accessed 2 October 2018)."}], "Title": "ICH\u2010GCP E6(R2) 2016"}, {"ReferenceList": [], "Reference": [{"Citation": "Imberger G, Vejlby AD, Hansen SB, M\u00f8ller AM, Wetterslev J. Statistical multiplicity in systematic reviews of anaesthesia interventions: a quantification and comparison between Cochrane and non\u2010Cochrane reviews. Plos One 2011;6(12):e28422.", "ArticleIdList": ["PMC3229598", "22164288"]}], "Title": "Imberger 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet 2014;383(9912):166\u201075.", "ArticleIdList": ["PMC4697939", "24411645"]}], "Title": "Ioannidis 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Jakobsen J, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta\u2010analytic methods. BMC Medical Research Methodology 2014;14:120. [DOI: 10.1186/1471-2288-14-120]", "ArticleIdList": ["10.1186/1471-2288-14-120", "PMC4251848", "25416419"]}], "Title": "Jakobsen 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct\u2010acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews 2017, Issue 9. [DOI: 10.1002/14651858.CD012143.pub3]", "ArticleIdList": ["10.1002/14651858.CD012143.pub3", "PMC6484376", "28922704"]}], "Title": "Jakobsen 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Jakobsen JC, Nielsen EE, Koretz RL, Gluud C. Do direct acting antivirals cure chronic hepatitis C?. BMJ (Clinical Research Ed.) 2018;10(361):k1382.", "ArticleIdList": ["29748173"]}], "Title": "Jakobsen 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technology Assessment 2009;13(35):1\u2010172.", "ArticleIdList": ["19607759"]}], "Title": "Jones 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Kemp R, \u00a0Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Medicine 2017;15(1):134.", "ArticleIdList": ["PMC5520356", "28728605"]}], "Title": "Kemp 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Keshavarz K, Kebriaeezadeh A, Alavian SM, Sari AA, Dorkoosh FA, Keshvari M, et al. Economic burden of hepatitis B virus\u2010related diseases: evidence from Iran. Hepatitis Monthly 2015;15(4):e25854.", "ArticleIdList": ["PMC4427913", "25977694"]}], "Title": "Keshavarz 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta\u2010analyses. Annals of Internal Medicine 2001;135(11):982\u20109.", "ArticleIdList": ["11730399"]}], "Title": "Kjaergard 2001"}, {"ReferenceList": [], "Reference": [{"Citation": "Krishna PM, Rao KN, Sandhya S, Banji D. A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Febaceae. Brazilian Journal of Pharmacognosy 2012;22(5):1145\u201054."}], "Title": "Krishna 2012"}, {"ReferenceList": [], "Reference": [{"Citation": "Lai WH. Lamivudine in combination with matrine for chronic hepatitis B. Journal of Community Medicine 2015;13(24):50\u20101."}], "Title": "Lai 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "Lee CF, Gong Y, Jesper B, Boxall EH, Cluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen\u2010positive mothers. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004790.pub2]", "ArticleIdList": ["10.1002/14651858.CD004790.pub2", "16625613"]}], "Title": "Lee 2006"}, {"ReferenceList": [], "Reference": [{"Citation": "Li JL, Huang HL. Epidemiological characteristics of adverse reaction of oxymatrine on database analyze. Anti\u2010tumor Pharmacy 2011;1(2):149\u201052."}], "Title": "Li 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Li XJ. One case of allergic shock caused by oxymatrine glucose injection. Journal of Pharmaceutical Research 2015;34(2):124."}], "Title": "Li 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "Li Q, Wang LL, Xu J, Shang XH, Wang CB. Matrine for treatment of carcinoma. International Journal of Laboratory Medicine 2017;38(4):500\u20102."}], "Title": "Li 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Liang N, Kong DZ, Ma SS, Lu CL, Yang M, Feng LD, et al. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B. Cochrane Database of Systematic Reviews 2019, Issue 4. [DOI: 10.1002/14651858.CD013089.pub2]", "ArticleIdList": ["10.1002/14651858.CD013089.pub2", "PMC6446139", "30941748"]}], "Title": "Liang 2018a"}, {"ReferenceList": [], "Reference": [{"Citation": "Liang N, Kong DZ, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus antiviral drugs for chronic hepatitis B. Cochrane Database of Systematic Reviews 2018, Issue 8. [DOI: 10.1002/14651858.CD013106]", "ArticleIdList": ["10.1002/14651858.CD013106", "PMC6589939", "31232459"]}], "Title": "Liang 2018b"}, {"ReferenceList": [], "Reference": [{"Citation": "Liu M, Liu XY, Cheng JF. Advance in the pharmacological research on matrine. China Journal of Chinese Materia Medica 2003;28(9):801\u20104.", "ArticleIdList": ["15015368"]}], "Title": "Liu 2003a"}, {"ReferenceList": [], "Reference": [{"Citation": "Liu JP, Zhu MH, Shi R, Yang M. Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. American Journal of Chinese Medicine 2003;31(3):337\u201054.", "ArticleIdList": ["12943166"]}], "Title": "Liu 2003b"}, {"ReferenceList": [], "Reference": [{"Citation": "Long Y, Lin XT, Zeng KL, Zhang L. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary & Pancreatic Diseases International 2004;3(1):69\u201072.", "ArticleIdList": ["14969841"]}], "Title": "Long 2004"}, {"ReferenceList": [], "Reference": [{"Citation": "Lu XH. Telbivudine in combination with matrine injection for treating chronic hepatitis B. Guide of China Medicine 2012;10(33):483\u20104."}], "Title": "Lu 2012"}, {"ReferenceList": [], "Reference": [{"Citation": "Lu JJ, Xu AQ, Wang J, Zhang L, Song LZ, Li RP, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Services Research 2013;13:37.", "ArticleIdList": ["PMC3572417", "23368750"]}], "Title": "Lu 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]", "ArticleIdList": ["10.1002/14651858.MR000033.pub3", "PMC8132492", "28207928"]}], "Title": "Lundh 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, et al. Biomedical research: increasing value, reducing waste. Lancet 2014;383(9912):101\u20104.", "ArticleIdList": ["24411643"]}], "Title": "Macleod 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Mallet V, Hamed K, Schwarzinger M. Prognosis of patients with chronic hepatitis B in France (2008\u20102013): a nationwide, observational and hospital\u2010based study. Journal of Hepatology 2017;66(3):514\u201020.", "ArticleIdList": ["27826056"]}], "Title": "Mallet 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Mao YM, Zeng MD, Lu LG, Wan MB, Li CZ, Chen CW, et al. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo\u2010controlled, multicenter clinical study. World Journal of Gastroenterology 2004;10(22):3269\u201073.", "ArticleIdList": ["PMC4572293", "15484298"]}], "Title": "Mao 2004"}, {"ReferenceList": [], "Reference": [{"Citation": "Higgins JP, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological Expectations of Cochrane Intervention Reviews, Version 1.07, 2018. community.cochrane.org/mecir\u2010manual (accessed prior to 30 May 2019)."}], "Title": "MECIR 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta\u2010analyses?. Lancet 1998;352(9128):609\u201013.", "ArticleIdList": ["9746022"]}], "Title": "Moher 1998"}, {"ReferenceList": [], "Reference": [{"Citation": "Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel\u2010group randomised trials. Lancet 2001;357(9263):1191\u20104.", "ArticleIdList": ["11323066"]}], "Title": "Moher 2001"}, {"ReferenceList": [], "Reference": [{"Citation": "Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PM, Korevaar DA, et al. Increasing value and reducing waste in biomedical research: who's listening?. Lancet 2016;387(10027):1573\u201086.", "ArticleIdList": ["26423180"]}], "Title": "Moher 2016"}, {"ReferenceList": [], "Reference": [{"Citation": "Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology 2013;66(7):736\u201042; quiz 742.e1\u20105. [PUBMED: 23623694]", "ArticleIdList": ["23623694"]}], "Title": "Mustafa 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, et al. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg\u2010negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open\u2010label study. Clinical Therapeutics 2008;30(2):317\u201023.", "ArticleIdList": ["18343270"]}], "Title": "Pellicelli 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta\u2010analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed.) 2009;339:b2700. [DOI: ]", "ArticleIdList": ["PMC2714672", "19622552"]}], "Title": "PRISMA 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, et al. Mortality for liver disease in patients with HIV infection: a cohort study. Journal of Acquired Immune Deficiency Syndromes 2000;24(3):211\u20107.", "ArticleIdList": ["10969344"]}], "Title": "Puoti 2000"}, {"ReferenceList": [], "Reference": [{"Citation": "Qi YT, Zuo WT. Entecavir plus matrine vs entecavir monotherapy for HBeAg\u2010positive chronic hepatitis B: a meta\u2010analysis. World Chinese Journal of Digestology 2013;21(15):1432\u20106."}], "Title": "Qi 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "Qin KM, Fang QB, Cai H, Cai BC. Summary of research on anticancer mechanism of constituent matrine. Journal of Shenzhen Polytechnic 2009;8(3):61\u20106."}], "Title": "Qin 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014."}], "Title": "Review Manager 2014 [Computer program]"}, {"ReferenceList": [], "Reference": [{"Citation": "Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591\u2010603.", "ArticleIdList": ["15095765"]}], "Title": "Royle 2003"}, {"ReferenceList": [], "Reference": [{"Citation": "Savovi\u0107 J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429\u201038.", "ArticleIdList": ["22945832"]}], "Title": "Savovi\u0107 2012a"}, {"ReferenceList": [], "Reference": [{"Citation": "Savovi\u0107 J, Jones H, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta\u2010epidemiological studies. Health Technology Assessment 2012;16(35):1\u201082.", "ArticleIdList": ["22989478"]}], "Title": "Savovi\u0107 2012b"}, {"ReferenceList": [], "Reference": [{"Citation": "Savovi\u0107 J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JP, et al. Association between risk\u2010of\u2010bias assessments and results of randomized trials in Cochrane Reviews: the ROBES meta\u2010epidemiologic study. American Journal of Epidemiology 2018;187(5):1113\u201022.", "ArticleIdList": ["PMC5928453", "29126260"]}], "Title": "Savovi\u0107 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408\u201012.", "ArticleIdList": ["7823387"]}], "Title": "Schulz 1995"}, {"ReferenceList": [], "Reference": [{"Citation": "Sch\u00fcnemann HJ. Interpreting GRADE's levels of certainty or quality of the evidence: GRADE for statisticians, considering review information size or less emphasis on imprecision?. Journal of Clinical Epidemiology 2016;75:6\u201015.", "ArticleIdList": ["27063205"]}], "Title": "Sch\u00fcnemann 2016"}, {"ReferenceList": [], "Reference": [{"Citation": "Shepherd J, Gospodarevskaya E, Frampton G, Cooper K. Entecavir for the treatment of chronic hepatitis B infection. Health Technology Assessment 2009;13(Suppl 3):31\u20106.", "ArticleIdList": ["19846026"]}], "Title": "Shepherd 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Song WJ, Luo J, Wu T, Yao SK. Oral oxymatrine preparation for chronic hepatitis B: a systematic review of randomized controlled trials. Chinese Journal of Integrative Medicine 2016;22(2):141\u20109.", "ArticleIdList": ["26016455"]}], "Title": "Song 2016"}, {"ReferenceList": [], "Reference": [{"Citation": "Storeb\u00f8 OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents \u2013 assessment of adverse events in non\u2010randomised studies. Cochrane Database of Systematic Reviews 2018, Issue 5. [DOI: 10.1002/14651858.CD012069.pub2]", "ArticleIdList": ["10.1002/14651858.CD012069.pub2", "PMC6494554", "29744873"]}], "Title": "Storeb\u00f8 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Student. The probable error of a mean. Biometrika 1908;6(1):1\u201025."}], "Title": "Student 1908"}, {"ReferenceList": [], "Reference": [{"Citation": "Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World Journal of Gastroenterology 2014;20(18):5427\u201034.", "ArticleIdList": ["PMC4017058", "24833873"]}], "Title": "Sunbul 2014"}, {"ReferenceList": [], "Reference": [{"Citation": "Tanabe N, Kuboyama T, Kazuma K, Konno K, Tohda C. The extract of roots of Sophora flavescens enhances the recovery of motor function by axonal growth in mice with a spinal cord injury. Frontiers in Pharmacology 2015;6:326.", "ArticleIdList": ["PMC4712302", "26834638"]}], "Title": "Tanabe 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "Thorlund K, Anema A, Mills E. Interpreting meta\u2010analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV\u2010infected individuals. Clinical Epidemiology 2010;2:57\u201066.", "ArticleIdList": ["PMC2943189", "20865104"]}], "Title": "Thorlund 2010"}, {"ReferenceList": [], "Reference": [{"Citation": "Thorlund K, Engstr\u00f8m J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for Trial Sequential Analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 16 January 2017)."}], "Title": "Thorlund 2011a"}, {"ReferenceList": [], "Reference": [{"Citation": "Thorlund K, Imberger G, Walsh M, Chu R, Gluud C, Wetterslev J, et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta\u2010analysis \u2013 a simulation study. PloS One 2011;6(10):e25491.", "ArticleIdList": ["PMC3196500", "22028777"]}], "Title": "Thorlund 2011b"}, {"ReferenceList": [], "Reference": [{"Citation": "Tong SP, Revill P. Overview of viral replication and genetic variability. Journal of Hepatology 2016;64(1 Suppl):S1\u2010S16.", "ArticleIdList": ["PMC4834849", "27084035"]}], "Title": "Tong 2016"}, {"ReferenceList": [], "Reference": [{"Citation": "Copenhagen Trial Unit. TSA \u2013 Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2011."}], "Title": "TSA 2011 [Computer program]"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang HW, Hou LJ, Li WW, Duan SP, Shen BS, Song XW. Clinical analysis of entecavir combined with Kushensu in treatment of chronic hepatitis B. China Continuing Medical Education 2015;7(15):195\u20106."}], "Title": "Wang 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang HL, Lu X, Yang X, Xu N. Antiviral therapy in lamivudine\u2010resistant chronic hepatitis B patients: a systematic review and network meta\u2010analysis. Gastroenterology Research and Practice 2016; Vol. 2016:3435965.", "ArticleIdList": ["PMC5031861", "27672391"]}], "Title": "Wang 2016a"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang XT, Lin HX, Zhang R. Lamivudine versus kushenin for chronic hepatitis B and YMDD mutation: a systematic review and meta\u2010analysis. Liaoning Journal of Traditional Chinese Medicine 2016;43(12):2478\u201083."}], "Title": "Wang 2016b"}, {"ReferenceList": [], "Reference": [{"Citation": "Wang XT, Lin HX, Zhang R. The clinical efficacy and adverse effects of interferon combined with matrine in chronic hepatitis B: a systematic review and meta\u2010analysis. Phytotherapy Research 2017;31(6):849\u201057.", "ArticleIdList": ["28382770"]}], "Title": "Wang 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta\u2010analysis. Journal of Clinical Epidemiology 2008;61(1):64\u201075.", "ArticleIdList": ["18083463"]}], "Title": "Wetterslev 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random\u2010effects model meta\u2010analyses. BMC Medical Research Methodology 2009;9:86.", "ArticleIdList": ["PMC2809074", "20042080"]}], "Title": "Wetterslev 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta\u2010analysis. BMC Medical Research Methodology 2017;17(1):39.", "ArticleIdList": ["PMC5397700", "28264661"]}], "Title": "Wetterslev 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1 (accessed 23 January 2018)."}], "Title": "WHO 2015"}, {"ReferenceList": [], "Reference": [{"Citation": "World Health Organization. Global hepatitis report, 2017. www.who.int/hepatitis/publications/global\u2010hepatitis\u2010report2017/en/ (accessed 13 July 2018)."}], "Title": "WHO 2017"}, {"ReferenceList": [], "Reference": [{"Citation": "World Health Organization. Hepatitis B fact sheets. www.who.int/en/news\u2010room/fact\u2010sheets/detail/hepatitis\u2010b (accessed 3 September 2018)."}], "Title": "WHO 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta\u2010epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601\u20105.", "ArticleIdList": ["PMC2267990", "18316340"]}], "Title": "Wood 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Wu YF. Sophorus Species for Chronic Hepatitis B and Viremic Carrier: a Systematic Review of Randomized Clinical Trials [Dissertation thesis]. Chaoyang Qu (China): Beijing University of Chinese Medicine, 2011."}], "Title": "Wu 2011a"}, {"ReferenceList": [], "Reference": [{"Citation": "Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD008960.pub2]", "ArticleIdList": ["10.1002/14651858.CD008960.pub2", "21491412"]}], "Title": "Xia 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD009004.pub2]", "ArticleIdList": ["10.1002/14651858.CD009004.pub2", "23633363"]}], "Title": "Xia 2013"}, {"ReferenceList": [], "Reference": [{"Citation": "Xu WS, Zhao KK, Miao XH, Ni W, Cai X, Zhang RQ, et al. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World Journal of Gastroenterology 2010;16(16):2028\u201037.", "ArticleIdList": ["PMC2860082", "20419842"]}], "Title": "Xu 2010"}, {"ReferenceList": [], "Reference": [{"Citation": "Yin WH, Ni HH. Entecavir in combination with Kushensu for treating HBeAg positive chronic hepatitis B. Clinical Rational Drug Use 2011;4(34):60\u20101."}], "Title": "Yin 2011"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF, et al. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacologica Sinica 2001;22(2):183\u20106.", "ArticleIdList": ["11741525"]}], "Title": "Zhang 2001a"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhang C, Nie HW, Cao XX. One case of fever induced by 0.6% oxymatrine salt water injection. Clinical Journal of Medical Officer 2008;9(4):635."}], "Title": "Zhang 2008"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhang CM. Combined application of oxymatrine and lamivudine in treating 62 cases of chronic hepatitis B. Clinical Medical Engineering 2012;19(6):935\u20106."}], "Title": "Zhang 2012"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhu YP. Chinese Materia Medica\u2010Chemistry, Pharmacology and Applications. 1st Edition. Boca Raton (FL): CRC Press, 1998."}], "Title": "Zhu 1998"}, {"ReferenceList": [], "Reference": [{"Citation": "Zhu ZC, Wang HZ, Yang F. Composite Sophorae injection in prevention of toxicity and adverse effects caused by chemotherapeutic agents. Journal of Practical Oncology 2009;24(6):592\u20104."}], "Title": "Zhu 2009"}, {"ReferenceList": [], "Reference": [{"Citation": "Zou YQ, Chen L, Yu CM. Preparation process of matrine and glucose injection. China Pharmacist 2009;12(12):1757\u20109."}], "Title": "Zou 2009"}], "Reference": [], "Title": "Additional references"}, {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Liang N, Kong DZ, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus antiviral drugs for chronic hepatitis B. Cochrane Database of Systematic Reviews 2018, Issue 8. [DOI: 10.1002/14651858.CD013106]", "ArticleIdList": ["10.1002/14651858.CD013106", "PMC6589939", "31232459"]}], "Title": "Liang 2018"}, {"ReferenceList": [], "Reference": [{"Citation": "Wu YF, Liao X, Liu JP. Sophorus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD008957]", "ArticleIdList": ["10.1002/14651858.CD008957", "21491412"]}], "Title": "Wu 2011b"}, {"ReferenceList": [], "Reference": [{"Citation": "Wu YF, Liao X, Liu JP. Sophorus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2018, Issue 8. [DOI: 10.1002/14651858.CD008957.pub2]", "ArticleIdList": ["10.1002/14651858.CD008957.pub2"]}], "Title": "Wu 2018"}], "Reference": [], "Title": "References to other published versions of this review"}], "History": [{"Year": "2019", "Month": "6", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "2", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "6", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "6", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["31232459", "PMC6589939", "10.1002/14651858.CD013106.pub2"]}}]}